A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.

Lugui Qiu,Junyuan Qi,Yuqin Song,Bo Jiang,Meifeng Tu,Lingyan Ping,Zengjun Li,Jun Zhu,Yuanyuan Xu,Hanying Bao,Zusheng Xu

A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.

2019

Lugui Qiu
Junyuan Qi
Yuqin Song
Bo Jiang
Meifeng Tu
Lingyan Ping
Zengjun Li
Jun Zhu
Yuanyuan Xu
Hanying Bao
Zusheng Xu

7563Background: YY-20394, an oral highly selective PI3Kδ inhibitor was studied in a phase I trial for patients with relapse or refractory B-cell malignancies. We characterized the safety, tolerabil...

Keywords:

Refractory
Pathology
Cancer research
Medicine
B cell
in patient
highly selective
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations